Himalaya Nutravedics India IPO Details: Key Dates, Price Band & Investment Overview

By Wealthova | Last Updated: September 16, 2026

Himalaya Nutravedics India Limited, an established player in the Ayurvedic and nutraceutical manufacturing sector, is gearing up to make its primary market debut with an upcoming ₹26.50 Crore SME IPO. Operating as a premier formulator and manufacturer of Ayurvedic and nutraceutical products, the company focuses on delivering high-quality healthcare formulations including Softgel Capsules, Tablets, Medicated Oils, and Liquid Orals. Operating a highly scalable and diverse business model, Himalaya Nutravedics provides comprehensive proprietary product portfolios and third-party contract manufacturing services, backed by the growing demand for holistic healthcare and dietary supplements. The subscription window for this book-built issue opens on September 22, 2026, and closes on September 24, 2026. The price band is set between ₹100 to ₹106 per equity share, comprising entirely of a fresh issue of 25.00 lakh shares (aggregating to ₹26.50 Crore) with absolutely no Offer for Sale (OFS) component. The company plans to utilize the fresh capital primarily to fund working capital requirements, support business development and digital marketing activities, and for general corporate purposes. Set to list on the BSE SME platform, market participants are closely watching this visible, healthcare-driven enterprise, backed by a strong FY26 total revenue of ₹43.12 Crore and a net profit of ₹7.39 Crore. Below, we break down the financial health, industry risk factors, and our honest Smart Market Insights to help you decide if you should subscribe to this issue!

Incorporated in June 2022 and headquartered in Hyderabad, Telangana, Himalaya Nutravedics India Limited is a fast-growing Ayurvedic and nutraceutical manufacturing enterprise. The company is actively engaged in the formulation, manufacturing, and marketing of a wide spectrum of holistic healthcare and dietary supplement products. Operating with a hybrid business model, the company balances its proprietary brand sales with a strong B2B contract manufacturing arm.

• Diverse Healthcare Formulations: The company’s core manufacturing capabilities cover a broad range of product delivery formats, including Softgel Capsules, Hardgel Capsules, Tablets, Liquid Orals, and Medicated Oils.
• Proprietary Branded Marketing: Himalaya Nutravedics actively markets its own branded Ayurvedic and nutraceutical portfolio directly to the market, relying primarily on strategic promotion through a network of healthcare practitioners.
• Third-Party Contract Manufacturing: In addition to its in-house brands, the company acts as a reliable manufacturing partner for other wellness brands, providing high-quality third-party contract manufacturing services that ensure steady capacity utilization and recurring revenue streams.

The Himalaya Nutravedics India IPO is a pure Fresh Issue of 25.00 Lakh equity shares aggregating to ₹26.50 Crore, with absolutely no Offer for Sale (OFS) by existing promoters. The company proposes to utilize the net proceeds from the fresh issue (amounting to approximately ₹21.25 Crore after deducting issue-related expenses) toward the following strategic objectives:

• Funding Working Capital Requirements: The largest portion of the net proceeds, ₹13.75 Crore, is strictly allocated to support the company's day-to-day working capital cycle. Given its dual model of proprietary sales and third-party contract manufacturing, maintaining optimal raw material inventory and managing extended receivable cycles is crucial for uninterrupted factory operations.
• Business Development and Digital Marketing Activities: The company has earmarked ₹7.50 Crore for aggressive business development and digital marketing initiatives. This capital will be deployed to expand its brand visibility, increase its product reach, and scale its presence across the Indian healthcare market.
• General Corporate Purposes: The remaining balance of the net proceeds will be deployed toward general corporate initiatives, administrative overheads, and covering the statutory expenses related to executing the public issue.